TET2

Methylcytosine dioxygenase TET2 · Q6N021 · TET2 on Sugi Atlas →

17,318 patent compounds predicted against TET2, 9,794 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL458815	0.64	6/20
SCHEMBL126063	0.56	6/20
Malic Acid (SCHEMBL89131)	0.55	6/20
Malic Acid (SCHEMBL95333)	0.52	6/20
Malic Acid (SCHEMBL118307)	0.52	6/20
Malic Acid (SCHEMBL121545)	0.52	6/20
Malic Acid (SCHEMBL123090)	0.52	6/20
Malic Acid (SCHEMBL162063)	0.52	6/20
Malic Acid (SCHEMBL162119)	0.52	6/20
Malic Acid (SCHEMBL163100)	0.52	6/20
Malic Acid (SCHEMBL215609)	0.52	6/20
Malic Acid (SCHEMBL217490)	0.52	6/20
Malic Acid (SCHEMBL220041)	0.52	6/20
Malic Acid (SCHEMBL631099)	0.52	6/20
Malic Acid (SCHEMBL631100)	0.52	6/20
Malic Acid (SCHEMBL637799)	0.52	6/20
Malic Acid (SCHEMBL672695)	0.52	6/20
Malic Acid (SCHEMBL674138)	0.52	6/20
Malic Acid (SCHEMBL733142)	0.52	6/20
Malic Acid (SCHEMBL887876)	0.52	6/20

Clinical trials — most relevant to TET2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC	PHASE3	UNKNOWN
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations	PHASE2	SUSPENDED
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker	PHASE2	NOT_YET_RECRUITING
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid	PHASE2	COMPLETED
Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS	PHASE2	UNKNOWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome	PHASE1/PHASE2	COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML	PHASE1/PHASE2	COMPLETED
Decitabine in Treating Patients With Myelofibrosis	PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma	PHASE1	RECRUITING
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma	PHASE1	SUSPENDED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL	PHASE1	ACTIVE_NOT_RECRUITING
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies	nan	UNKNOWN
MIF Involvement in AML	nan	ACTIVE_NOT_RECRUITING
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test	nan	UNKNOWN
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy	nan	UNKNOWN
Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity	nan	UNKNOWN
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms	nan	RECRUITING
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes	nan	COMPLETED
Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study	nan	COMPLETED
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN
Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction	nan	NOT_YET_RECRUITING
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer	nan	RECRUITING
Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TET2 binder may also engage these)

Protein	Name	Similarity
TET1	Methylcytosine dioxygenase TET1	0.999	landscape →
Q3URK3	—	0.997	Q3URK3 →
Q5DTW7	—	0.996	Q5DTW7 →
Q4JK59	—	0.995	Q4JK59 →
A6NCI8	—	0.994	A6NCI8 →
Q3V0A6	—	0.994	Q3V0A6 →
Q6P1W5	—	0.994	Q6P1W5 →
Q925H1	—	0.992	Q925H1 →
Q9Y2F5	—	0.992	Q9Y2F5 →
Q8BG36	—	0.992	Q8BG36 →
Q9HCM1	—	0.991	Q9HCM1 →
Q90469	—	0.991	Q90469 →
Q9YGT5	—	0.990	Q9YGT5 →
Q5QGS0	—	0.990	Q5QGS0 →
Q9P2H0	—	0.990	Q9P2H0 →
Q6NS59	—	0.990	Q6NS59 →
Q7Z570	—	0.989	Q7Z570 →
E9Q286	—	0.989	E9Q286 →
MAP3K19	Mitogen-activated protein kinase kinase kinase 19	0.989	landscape →
ASH1L	Histone-lysine N-methyltransferase ASH1L	0.989	landscape →
Q0VAV2	—	0.989	Q0VAV2 →
Q80U44	—	0.989	Q80U44 →
Q2KHR3	—	0.988	Q2KHR3 →
Q1KKW8	—	0.988	Q1KKW8 →
Q6YXZ4	—	0.988	Q6YXZ4 →
Q6J6I9	—	0.988	Q6J6I9 →
A0JP82	—	0.988	A0JP82 →
Q4KL20	—	0.988	Q4KL20 →
Q98SH9	—	0.988	Q98SH9 →
Q28DZ0	—	0.988	Q28DZ0 →